JPRN-UMIN000035653已完成未知
Denosumab prevents periprosthetic bone mineral density loss in the tibial metaphysis in total knee arthroplasty - The effect of denosumab in periprosthetic bone mineral density
Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine0 个研究点目标入组 28 人开始时间: 2019年1月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •We exclude patients who are undergoing revision surgery, and those who had previously taken anti-osteoporotic drugs or other medications known to influence bone mineral metabolism.
研究者
相似试验
进行中（未招募）
1 期
A study to see if a drug called Denosumab, affecting bone tissue and mineralization of the bone, will improve the outcome of Total Hip replacement surgery.EUCTR2013-004940-48-SEDanderyds Hospital, Department of Clinical Sciences, Division of Orthopaedics110
Unknown
2 期
Denosumab for Treating Periprosthetic Osteolysis.OsteolysisNCT02299817Olof Skoldenberg20
进行中（未招募）
不适用
A clinical trial to find out whether a medication, called denosumab, has an effect on the bone surrounding a hip joint replacementEUCTR2011-000541-20-GBSheffield Teaching Hospitals NHS Foundation Trust30
已完成
4 期
The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee ArthroplastyBone ResorptionNCT02760979Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau60
已完成
2 期
Denosumab and Osteoporotic Vertebral Compression FractureOsteoporotic Vertebral Compression FractureNCT05058443Shenzhen People's Hospital90